Molecular Partners (MOLN) Leerink Global Healthcare Conference 2026 summary

Company overview and technology

• Focuses on mini-proteins called DARPins, engineered for high-affinity binding and multi-specificity, with applications in radiotherapy and T cell engagement.

• DARPins offer advantages of small size, stability, and tunable half-life, bridging the gap between peptides and antibodies.

• Seven clinical DARPins developed, with extensive engineering for application-specific half-lives.

Strategic priorities and platform focus

• Radiotherapy is the primary focus (80% of activity), with T cell engagers as a secondary area (20%).

• Radiotherapy offers attractive ROI due to lower investment needed for early clinical data compared to T cell engagers.

• Isotope selection is tailored to each program, with partnerships for lead and actinium supply.

Radio-DARPin programs and clinical development

• Compassionate care programs enable early de-risking and learning, with recent DLL3 program data presented in South Africa.

• DLL3 is a validated, tumor-specific target with persistent expression and rapid receptor cycling, offering unique PK advantages.

• Imaging data for MP0712 shows strong, specific tumor uptake, clean safety, and favorable dosimetry.

• Phase I for MP0712 is underway with a four-dose escalation design; first safety data expected by end of H1, activity data by end of H2, and response rates in H1 next year.

• Mesothelin (MP0726) chosen for its challenging biology; clinical compassionate care imaging expected to start in Q3.